博聞科技(600883.SH)第四大股東質押480萬股
格隆匯10月24日丨博聞科技(600883.SH)公佈,2019年10月15日,公司第四大股東永昌投資公司與山西證券辦理了約定購回式證券交易業務,交易標的為所持有的公司760萬股,佔公司總股本的3.22%,購回期限為365天。
2019年10月24日,公司收到永昌投資公司的通知,永昌投資公司為上述約定購回式證券交易提供增信,將其持有公司的480萬股股份進行了質押,並在中國證券登記結算有限公司上海分公司完成質押登記手續。
截至本公告日,永昌投資公司持有公司股份數量793.17萬股,佔公司總股本的3.36%,其中處於質押凍結狀態的股份數量為480萬股,佔公司總股本的2.03%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.